Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s Crestor Pending At FDA For Atherosclerosis

This article was originally published in The Pink Sheet Daily

Executive Summary

Pivotal METEOR study indicates Crestor slows, but does not reverse, arterial plaque build-up in low-risk patients.

You may also be interested in...



Crestor Atherosclerosis Indication Adds Point Of Difference, Brand Leader Says

AstraZeneca will build atherosclerosis benefit of Crestor into “messaging” of the statin to physicians, Commercial Brand Leader Nanfra says in an interview with “The Pink Sheet” DAILY.

Crestor Atherosclerosis Indication Adds Point Of Difference, Brand Leader Says

AstraZeneca will build atherosclerosis benefit of Crestor into “messaging” of the statin to physicians, Commercial Brand Leader Nanfra says in an interview with “The Pink Sheet” DAILY.

AstraZeneca To File For Additional Crestor Claim In First Half 2007

The company is awaiting results from its METEOR clinical trials before putting together a regulatory package.

Related Content

Topics

UsernamePublicRestriction

Register

PS065811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel